Product Description
Mechanisms of Action: COMT Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Algeria | Argentina | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Chile | China | Colombia | Croatia | Cyprus | Czech | Dominican Republic | Ecuador | Egypt | Estonia | France | Germany | Greece | Hong Kong | Hungary | India | Italy | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | Spain | Sri Lanka | Switzerland | Taiwan | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Primus
Company Location:
Company Founding Year: None
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 4: Venous Insufficiency|Varicose Veins|Pelvic Pain|Chronic Pain|Forearm Injuries|Postthrombotic Syndrome|Venous Thrombosis|Lymphedema|Edema|Postphlebitic Syndrome|Anal Fistula|Rectal Fistula
Phase 3: Hemorrhoids|Infertility|Ovarian Hyperstimulation Syndrome|Venous Insufficiency|Chronic Pain|Cellulite|Edema|Lipodystrophy|Pelvic Pain|Inflammation|Depressive Disorder|Ovarian Diseases|Common Bile Duct Diseases|Abdominal Pain|Varicose Veins|Kidney Diseases|Hypertension, Renal|Uterine Diseases|Vaginal Diseases|Leukocyte Disorders|Bile Reflux|Breast Cancer|Breast Diseases|Non-alcoholic Steatohepatitis|Peripheral Nervous System Diseases|Colitis, Ulcerative|Fatty Liver, Alcoholic|Peptic Ulcer|Arthritis, Rheumatoid|Hepatitis, Alcoholic
Phase 1: Coronavirus Infections|Acute Respiratory Distress Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06256575 |
PVDUS-01 | N/A |
Recruiting |
Skin Ulcer|Scleroderma, Diffuse |
2027-07-15 |
2025-07-11 |
Primary Endpoints |
|
NCT06367166 |
RyazanSMU | N/A |
Active, not recruiting |
Varicose Veins|Edema |
2026-04-01 |
2024-04-17 |
Primary Endpoints|Treatments |
|
ChiCTR2500111472 |
ChiCTR2500111472 | N/A |
Not yet recruiting |
Osteoarthritis, Knee |
2026-03-31 |
|||
NCT07300735 |
IRB NO:12098 | N/A |
Recruiting |
Neutropenia |
2026-03-01 |
2025-12-30 |
Primary Endpoints|Start Date|Treatments|Trial Status |
|
NCT07185386 |
VSV-25-001 | N/A |
Recruiting |
Prodromal Symptoms|Venous Insufficiency |
2026-01-31 |
2025-09-23 |
Primary Endpoints|Treatments |
|
NCT06753448 |
NCT06753448 | N/A |
Completed |
Total Knee Arthroplasty|Venous Insufficiency |
2025-06-10 |
2025-07-16 |
Primary Endpoints |
|
NCT06352099 |
ESPINS | N/A |
Completed |
Hypertension |
2024-11-15 |
2025-03-28 |
Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT06333691 |
Aya Mohammed | N/A |
Completed |
Ovarian Hyperstimulation Syndrome |
2024-02-01 |
2025-01-08 |
Primary Endpoints|Treatments |
|
NCT05750563 |
OPGIE/0122/FS | N/A |
Unknown status |
Hemorrhoids |
2023-10-15 |
2025-02-04 |
Primary Endpoints|Treatments|Trial Status |
|
ChiCTR2100049077 |
ChiCTR2100049077 | N/A |
Not yet recruiting |
Total Knee Arthroplasty |
2022-12-30 |
|||
NCT04933591 |
NIS-ВЕН-19.03 | N/A |
Completed |
Varicose Veins |
2021-08-28 |
2022-04-01 |
||
ChiCTR1900022531 |
ChiCTR1900022531 | N/A |
Not yet recruiting |
Unknown |
2020-08-01 |
|||
NCT05158192 |
HP8834-01 | P1 |
Completed |
Acute Respiratory Distress Syndrome |
2021-12-14 |
50% |
2022-02-17 |
Primary Endpoints|Treatments|Trial Status |
NCT04452799 |
NCT04452799 | P1 |
Unknown status |
Coronavirus Infections |
2020-10-01 |
2022-06-03 |
Primary Endpoints|Treatments|Trial Status |
|
NCT06811220 |
NCT06811220 | P3 |
Not yet recruiting |
Breast Diseases|Breast Cancer|Peripheral Nervous System Diseases |
2025-12-31 |
2025-02-07 |
||
NCT05756179 |
NCT05756179 | P3 |
Recruiting |
Arthritis, Rheumatoid |
2025-09-01 |
2024-09-20 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
|
NCT06584799 |
VENOTREAT | P3 |
Recruiting |
Leukocyte Disorders|Bile Reflux|Depressive Disorder|Chronic Pain|Varicose Veins|Hypertension, Renal|Kidney Diseases|Pelvic Pain|Edema|Abdominal Pain|Common Bile Duct Diseases|Uterine Diseases|Ovarian Diseases|Vaginal Diseases|Inflammation |
2025-01-01 |
2024-09-06 |
||
NCT05670457 |
diosmin peptic ulcer | P3 |
Unknown status |
Peptic Ulcer |
2024-06-01 |
2025-06-03 |
Primary Endpoints|Treatments|Trial Status |
|
NCT05626166 |
NCT05626166 | P3 |
Unknown status |
Colitis, Ulcerative |
2023-11-01 |
2025-04-02 |
Primary Endpoints|Treatments|Trial Status |
|
NCT05942547 |
3626MS202/6/23 | P3 |
Unknown status |
Non-alcoholic Steatohepatitis|Fatty Liver, Alcoholic|Hepatitis, Alcoholic |
2023-10-10 |
2025-07-02 |
Primary Endpoints|Trial Status |
|
ACTRN12614000535673 |
ACTRN12614000535673 | P3 |
Recruiting |
Ovarian Hyperstimulation Syndrome |
2019-09-29 |
2024-08-29 |
Treatments |
|
NCT06184438 |
N202309013 | P4 |
Completed |
Rectal Fistula|Anal Fistula |
2025-01-01 |
2025-05-17 |
Primary Completion Date|Primary Endpoints |
|
NCT04360889 |
MDA-1 | P4 |
Completed |
Lymphedema |
2022-08-03 |
2022-08-05 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
NCT04358497 |
ENDPCS | P4 |
Unknown status |
Varicose Veins|Chronic Pain|Pelvic Pain |
2022-07-31 |
2022-10-06 |
||
NCT03413618 |
RIDILOTT-DVT | P4 |
Completed |
Postthrombotic Syndrome|Postphlebitic Syndrome|Venous Thrombosis |
2019-07-31 |
2019-03-22 |
Treatments |